- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02286947
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Study Overview
Detailed Description
This is an open-label, multi-center study to explore the safety and tolerability of eteplirsen injection in participants with advanced stage DMD with confirmed genetic mutations amenable to treatment by exon 51 skipping.
Participants will be evaluated for inclusion during a Screening/Baseline period of up to 4 weeks. Eligible participants will receive once weekly intravenous (IV) infusions of 30 mg/kg eteplirsen for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Safety will be regularly assessed throughout the study via the collection of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Ronald Reagan UCLA Medical Center
-
Sacramento, California, United States, 95817
- University of California, Davis Medical Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Children's Hospital
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Kennedy Krieger Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- St. Louis Children's Hospital
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male 7 - 21 years of age
- Diagnosis of DMD with a mutation that is amenable to exon 51 skipping, confirmed by a genetic report
- Stable dose of oral corticosteroids for at least 24 weeks or has not received corticosteroids for at least 24 weeks
- Non-ambulatory, or incapable of walking ≥300 meters on the 6-Minute Walk Test (6MWT).
- Score of ≤4 on the Brooke Score for Arms and Shoulders.
- Stable cardiac and pulmonary function
- Use of contraceptives for sexually active males throughout the study
- Willing to provide consent and comply with the study
Exclusion Criteria:
- Use of any pharmacologic treatment (other than corticosteroids) within 12 weeks that may have an effect on muscle strength or function (e.g., growth hormone, anabolic steroids).
- Previous treatment with SMT C1100/BMN 195 at any time.
- Previous treatment with drisapersen (PRO051) within the last 6 months.
- Participation in any other DMD interventional clinical study within 12 weeks
- Major change in physiotherapy regimen within the past 3 months
- Major surgery within 3 months
- Presence of other clinically significant illness
- Use of an aminoglycoside antibiotic within 12 weeks or the need for this antibiotic or statin during study
- Forced vital capacity % predicted [FVC % predicted] <40%, or requiring daytime ventilation.
- Require antiarrhythmic and/or antidiuretic therapy for heart failure.
- Have a left ventricular ejection fraction (LVEF) of <40%.
- Prior or ongoing medical condition that could adversely affect the safety of the patient, make it unlikely that the course of treatment would be completed, or impair the assessment of study results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eteplirsen 30 mg/kg
Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
|
Eteplirsen solution for IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events
Time Frame: From first dose of drug up to 100 weeks
|
An adverse event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug.
A serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent AEs were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug (up to 100 weeks) that were absent before treatment or that worsened relative to pretreatment state.
AEs included both serious and non-serious adverse events.
|
From first dose of drug up to 100 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities
Time Frame: Baseline up to 100 weeks
|
Laboratory parameters included hematology, clinical chemistry, urinalysis and coagulation. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal findings. Incr=increase; LLN=lower limit of normal; ULN=upper limit of normal; GGT=gamma glutamyl transferase |
Baseline up to 100 weeks
|
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
Time Frame: Baseline up to 100 weeks
|
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature.
Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal vital sign findings.
|
Baseline up to 100 weeks
|
Number of Participants With at Least One Potentially Clinically Significant Abnormalities in Physical Examinations
Time Frame: Baseline up to 100 weeks
|
Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations).
Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems.
Brief physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; and skin.
|
Baseline up to 100 weeks
|
Number of Participants With Abnormalities in Electrocardiograms (ECGs)
Time Frame: Baseline up to 100 weeks
|
Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the patient was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. The Investigator reviewed the results of the centrally read ECG report and determined if the findings were clinically significant. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal ECG findings. msec=milliseconds; QTcF=QT interval corrected with Fridericia's method |
Baseline up to 100 weeks
|
Number of Participants With Abnormalities in Echocardiograms (ECHO)
Time Frame: Baseline up to 100 weeks
|
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. The ECHO was reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. Ejection fraction was noted. The Investigator reviewed the results of the ECHO report and determined if the findings were clinically significant. LEVF=left ventricular ejection fraction |
Baseline up to 100 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Sarepta Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4658-204
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscular Dystrophy, Duchenne
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
Clinical Trials on Eteplirsen
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular DystrophyBelgium, France, Italy, United Kingdom
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular DystrophyUnited States
-
Sarepta Therapeutics, Inc.TerminatedDuchenne Muscular DystrophyBelgium, France, Italy, United Kingdom
-
Sarepta Therapeutics, Inc.Completed
-
Sarepta Therapeutics, Inc.British Medical Research CouncilCompletedDuchenne Muscular DystrophyUnited Kingdom
-
Sarepta Therapeutics, Inc.Active, not recruitingMuscular Dystrophy, DuchenneUnited States, Korea, Republic of, India, Slovenia, Turkey, United Kingdom, Germany, Switzerland, Spain, Czechia, France, Serbia, Taiwan, Netherlands, Mexico, Colombia, Denmark, New Zealand, Norway, Greece, Hungary, Ireland, Italy, Jo... and more
-
Kevin FlaniganSarepta Therapeutics, Inc.Completed